financetom
Business
financetom
/
Business
/
UBS Comments on Canadian Dollar
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UBS Comments on Canadian Dollar
Feb 7, 2025 4:42 AM

07:20 AM EST, 02/07/2025 (MT Newswires) -- The focal point of late has undoubtedly been United States President Donald Trump's proposed tariffs on Canadian goods shipped to the U.S., said UBS.

A 25% universal tariff rate would be troublesome for the Canadian economy -- despite the exemption for energy products, wrote the bank in a note to clients. But it would also have a notable stagflationary effect on the U.S. -- making it an expensive strategy for Trump.

Further, Canada laid out its retaliation strategy which is designed to respond in kind. UBS still thinks the tariffs won't be implemented in that form and "deal making" will remain key in the Trump administration's strategy.

Canada remains in a weak negotiation spot politically without a functioning government in place and new elections likely later in Q2, stated the bank.

In addition, the economy is hurting given its high interest-rate sensitivity and elevated Bank of Canada (BoC) policy rates for some time.

Accordingly, the BoC struck a cautious tone in their policy meeting last week and noted its readiness to react to any economic shock concerning U.S. tariffs.

This would be much needed given fiscal stimulus is unlikely to come to the rescue given parliament remains prorogued until March, pointed out the bank.

The market reaction to Trump's proposed tariffs was rather benign and was completely reversed following the delay in implementation. From here, UBS doesn't see much of a risk premium priced into USDCAD and, rather, the pair trades below what rates differentials suggest.

While the bank doesn't expect the tariffs to be implemented in the mentioned form, a risk of some adverse trade action remains. UBS thinks USDCAD can test 1.46 again in the coming months before edging lower later in the year.

Broader US dollar (USD) strength might also be enough to get there -- even in the absence of tariffs on Canada, according to the bank.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Finance guide could spur extra $200 billion for sustainable development, JPMorgan says
Finance guide could spur extra $200 billion for sustainable development, JPMorgan says
Oct 23, 2024
* Impact disclosure guidance released by Taskforce * Group chaired by JPMorgan ( JPM ), Natixis * Aims to help countries, companies raise impact finance By Karin Strohecker and Simon Jessop WASHINGTON, Oct 23 (Reuters) - A new guide for countries and companies seeking financing for activities that have a positive and verifiable social or environmental impact could unlock an...
Synaptics Expands Taiwan Presence, Operations
Synaptics Expands Taiwan Presence, Operations
Oct 23, 2024
03:57 AM EDT, 10/23/2024 (MT Newswires) -- Synaptics ( SYNA ) said late Tuesday it has expanded in the Taiwanese city of Hsinchu, making Taiwan the company's largest base of personnel worldwide. The company said the expansion gives it headroom to grow both its essential operations and engineering expertise. The facilities will house the team developing its AI-enabled devices for...
--Mueller Water Products Increases Quarterly Dividend to $0.067 per Share From $0.064; Payable Nov. 20 to Shareholders of Record on Nov. 8
--Mueller Water Products Increases Quarterly Dividend to $0.067 per Share From $0.064; Payable Nov. 20 to Shareholders of Record on Nov. 8
Oct 23, 2024
04:03 AM EDT, 10/23/2024 (MT Newswires) -- Price: 22.01, Change: -0.06, Percent Change: -0.27 ...
Alto Neuroscience Says Phase 2b Study in Major Depressive Disorder Fails to Meet Primary Endpoint
Alto Neuroscience Says Phase 2b Study in Major Depressive Disorder Fails to Meet Primary Endpoint
Oct 23, 2024
04:06 AM EDT, 10/23/2024 (MT Newswires) -- Alto Neuroscience ( ANRO ) said late Tuesday a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo. Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, Alto Neuroscience ( ANRO...
Copyright 2023-2025 - www.financetom.com All Rights Reserved